Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Shearman & Sterling LLP ordered by Published Date Descending.
Links to Result pages
Eastern District Of Pennsylvania Denies In Part And Grants In Part Motion To Dismiss Stock Drop Suit, Finding Plaintiffs Adequately Pled Global Pharmaceutical Company Misrepresented The Safety Of Its Opioid
On December 10, 2018, Judge Timothy J. Savage of the United States District Court for the Eastern District of Pennsylvania denied in large part defendants' motion to dismiss a putative class action asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Sections 11 and 20 of the Securities Act of 1933 (the "Securities Act").
United States
20 Dec 2018
Putative Securities Class Action Dismissed Against Biopharmaceutical Company Where Statements Regarding Clinical Trials Were Not Actionable And Plaintiffs Failed To Plead Scienter
The Company develops antibiotics to treat infectious diseases, and was working on developing and releasing solithromycin, a drug for community-acquired bacterial pneumonia.
United States
9 Nov 2018
Northern District Of California Dismisses Class Action Against Biopharmaceutical Company Alleging Fraud Based On Undisclosed Problems With Hepatitis B Vaccine In Trials And FDA Approval Process
On June 4, 2018, Judge Yvonne Gonzalez Rogers of the United States District Court for the Northern District of California dismissed with prejudice a class action alleging that Dynavax...
United States
13 Jun 2018
Northern District Of California Certifies Class In Securities Fraud Action Against Medical Device Manufacturer
On May 8, 2018, Judge Claudia Wilken of the United States District Court for the Northern District of California granted class certification in an action asserting claims ...
United States
16 May 2018
Section 219 Iran Notices Update: Disclosure Dynamics In The Era Of Relaxed Iran Sanctions
It has now been two years since Iran-related sanctions relief took effect under the Joint Comprehensive Plan of Action.
6 Mar 2018
Kessel And Masella Write Article On Helping Biotechs Prepare For Crises
How can you prepare for the day when an unexpected event morphs into a crisis, with all the potential negative repercussions for your company's reputation and financial standing?
United States
9 Feb 2016
Neglected Diseases, Delinquent Diagnostics
Diagnostic tests constitute 3 to 5% of health care spending but Influence ~70% of health care decisions.
United States
19 Mar 2014
FTC Workshop Seeks To Spark Biosimilars Competition
Demand for biologics is growing fast, but even after Congress passed authorizing legislation in 2010, the pace of generic entry appears to have stalled.
United States
13 Feb 2014
Do You Really Want To Be A Biotech Board Member?
There are many advantages to becoming a company advisor, but academics should think carefullyabout the legal and personal implications before accepting a seat on the board.
United States
6 Dec 2013
Links to Result pages